IDEAYA Biosciences, Inc.
IDYA · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.82 | 0.11 | -0.03 | 1.12 |
| FCF Yield | -3.40% | -4.26% | -5.47% | -1.82% |
| EV / EBITDA | -19.95 | -16.13 | -15.19 | -35.12 |
| Quality | ||||
| ROIC | -9.00% | -8.03% | -13.37% | -5.58% |
| Gross Margin | 0.00% | 0.00% | 90.81% | 0.00% |
| Cash Conversion Ratio | 1.19 | 0.81 | 0.84 | 0.93 |
| Growth | ||||
| Revenue 3-Year CAGR | 109.14% | -46.28% | -47.16% | -48.39% |
| Free Cash Flow Growth | -2.38% | 49.76% | -147.04% | -46.78% |
| Safety | ||||
| Net Debt / EBITDA | 0.99 | 1.25 | 0.45 | 5.70 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -2,158.42 | 0.00 |